Generation of breast cancer stem cells through epithelial-mesenchymal transition.

PubWeight™: 8.97‹?› | Rank: Top 0.1%

🔗 View Article (PMC 2492808)

Published in PLoS One on August 06, 2008

Authors

Anne-Pierre Morel1, Marjory Lièvre, Clémence Thomas, George Hinkal, Stéphane Ansieau, Alain Puisieux

Author Affiliations

1: Centre Léon Bérard, Lyon, France.

Articles citing this

(truncated to the top 100)

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90

The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol (2009) 8.63

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A (2010) 6.15

Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell (2012) 5.44

Cancer stem cells: mirage or reality? Nat Med (2009) 5.20

Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell (2011) 4.79

Slug and Sox9 cooperatively determine the mammary stem cell state. Cell (2012) 4.77

The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer? EMBO Rep (2010) 4.05

Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol (2010) 4.04

The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med (2013) 3.96

Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle (2009) 3.68

Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev (2013) 3.63

Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell (2013) 3.61

To differentiate or not--routes towards metastasis. Nat Rev Cancer (2012) 3.59

Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev (2009) 3.58

Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30

Unravelling cancer stem cell potential. Nat Rev Cancer (2013) 3.06

Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol (2009) 2.89

Cancer stem cells: the challenges ahead. Nat Cell Biol (2013) 2.78

Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov (2014) 2.55

EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res (2011) 2.32

The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J (2011) 2.29

Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One (2010) 2.15

Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer (2011) 2.14

Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A (2012) 2.13

G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J Clin Invest (2012) 2.12

The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia (2010) 2.12

TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst (2014) 2.08

Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res (2009) 2.05

A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol (2014) 2.01

Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev (2010) 1.99

Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat (2010) 1.98

Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res (2011) 1.96

The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol (2010) 1.96

Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis (2009) 1.94

Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol (2009) 1.90

Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. Trends Cell Biol (2015) 1.87

Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell (2013) 1.86

Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer (2009) 1.85

Highly coordinated proteome dynamics during reprogramming of somatic cells to pluripotency. Cell Rep (2012) 1.84

Kruppel-like factor 4 inhibits epithelial-to-mesenchymal transition through regulation of E-cadherin gene expression. J Biol Chem (2010) 1.79

Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer (2011) 1.79

FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res (2013) 1.76

Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. J Mammary Gland Biol Neoplasia (2010) 1.76

Ubiquitously transcribed genes use alternative polyadenylation to achieve tissue-specific expression. Genes Dev (2013) 1.74

Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res (2011) 1.71

Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov (2012) 1.71

Transforming growth factor-β and the hallmarks of cancer. Cell Signal (2010) 1.66

TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res (2011) 1.65

Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res (2011) 1.57

SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype. BMC Cancer (2010) 1.56

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med (2012) 1.55

Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res (2013) 1.54

Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression. Cell Tissue Res (2011) 1.53

Tissue-based identification of stem cells and epithelial-to-mesenchymal transition in breast cancer. Hum Pathol (2013) 1.50

Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Res (2011) 1.50

Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene (2012) 1.49

EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. PLoS Genet (2012) 1.47

Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. Dig Dis Sci (2010) 1.45

Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One (2010) 1.44

Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther (2012) 1.44

Clinical significance of epithelial-mesenchymal transition. Clin Transl Med (2014) 1.44

Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer. Am J Pathol (2015) 1.44

Autophagy in stem cells. Autophagy (2013) 1.43

Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. J Biol Chem (2009) 1.42

Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res (2009) 1.40

Prognostic Molecular Subtypes of Low-Grade Cancer of the Appendix. J Am Coll Surg (2015) 1.39

Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem (2012) 1.37

An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. Cancer Cell (2013) 1.36

Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med (2012) 1.35

Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer. Cell Cycle (2011) 1.34

Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One (2012) 1.32

Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res (2011) 1.31

Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One (2012) 1.31

Up-regulation of sonic hedgehog contributes to TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS One (2011) 1.30

Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast. BMC Cancer (2009) 1.29

HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget (2013) 1.29

MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition. Oncogene (2013) 1.29

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat (2013) 1.27

AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene (2013) 1.27

Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci U S A (2009) 1.26

The biology of head and neck cancer stem cells. Oral Oncol (2011) 1.25

Breast cancer stem cells. Int J Biochem Cell Biol (2012) 1.25

Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat (2012) 1.24

Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression. Breast Cancer Res (2010) 1.24

miR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling. J Biol Chem (2010) 1.24

Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol (2012) 1.24

CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med (2012) 1.23

ATF3, an adaptive-response gene, enhances TGF{beta} signaling and cancer-initiating cell features in breast cancer cells. J Cell Sci (2010) 1.23

Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One (2010) 1.23

p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One (2012) 1.22

The Regulatory Role of MicroRNAs in EMT and Cancer. J Oncol (2015) 1.22

Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. Cancer Res (2010) 1.21

SOX2 contributes to melanoma cell invasion. Lab Invest (2011) 1.21

Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol (2012) 1.20

Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer. Oncotarget (2014) 1.19

Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 1.18

The relevance of the TGF-β Paradox to EMT-MET programs. Cancer Lett (2013) 1.18

Tumorigenesis: Twist1 links EMT to self-renewal. Nat Cell Biol (2010) 1.17

Articles cited by this

Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17

The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08

Identification of human brain tumour initiating cells. Nature (2004) 38.87

Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer (2002) 34.99

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2006) 24.52

Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59

In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev (2003) 20.77

Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res (2005) 13.89

Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A (2007) 13.58

The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med (2007) 13.39

Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90

Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52

Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev (2001) 11.25

Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A (2000) 10.88

Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer (2005) 9.04

Applying the principles of stem-cell biology to cancer. Nat Rev Cancer (2003) 8.95

Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ (2007) 8.08

CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res (2006) 6.35

MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell (2004) 5.98

Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res (2006) 5.90

TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev (1996) 5.71

Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev (2003) 4.71

Self-renewal and solid tumor stem cells. Oncogene (2004) 4.60

Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell (2007) 4.30

AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci U S A (2000) 3.68

CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer (2007) 3.65

Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun (2006) 3.35

Cancer stem cells--old concepts, new insights. Cell Death Differ (2008) 2.56

Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res (2004) 2.45

A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood (2000) 2.42

MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell (2003) 2.33

Sorting out breast-cancer gene signatures. N Engl J Med (2007) 2.22

Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood (2000) 1.88

Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res (2007) 1.63

Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia (2002) 1.35

Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther (1995) 1.34

Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia. Blood (1995) 1.30

Articles by these authors

Metastasis: a question of life or death. Nat Rev Cancer (2006) 6.26

Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell (2008) 5.88

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32

Retracted Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol (2009) 3.84

Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31

Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res (2010) 2.99

A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell (2013) 2.46

Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol (2003) 2.05

Human telomeric position effect is determined by chromosomal context and telomeric chromatin integrity. EMBO Rep (2002) 1.79

Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell (2004) 1.71

Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet (2009) 1.55

Influence of neuroblastoma stage on serum-based detection of MYCN amplification. Pediatr Blood Cancer (2009) 1.49

EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. PLoS Genet (2012) 1.47

Gadd45a activation protects melanoma cells from ultraviolet B-induced apoptosis. J Invest Dermatol (2007) 1.47

A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. Int J Cancer (2006) 1.44

MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary nonpolyposis colorectal cancer. Cancer Res (2002) 1.41

Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med (2009) 1.36

p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer. Cancer Cell (2013) 1.35

The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells (2010) 1.34

Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res (2012) 1.26

Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene (2003) 1.25

Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing. Hum Mutat (2006) 1.25

Cancer stem cells: the emerging challenge of drug targeting. Curr Med Chem (2009) 1.17

p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol (2006) 1.14

BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. Blood (2008) 1.10

C. elegans homologue of the Caf1 gene, which encodes a subunit of the CCR4-NOT complex, is essential for embryonic and larval development and for meiotic progression. Gene (2005) 1.09

Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat (2011) 1.04

IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep (2013) 1.03

Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type. Hum Genet (2002) 1.03

Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Cancer Res (2002) 1.02

Retracted Structure and functional analysis of the MYND domain. J Mol Biol (2006) 1.02

PLA2R1 mediates tumor suppression by activating JAK2. Cancer Res (2013) 1.01

The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells. J Cell Sci (2005) 0.99

Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a likely cause of PMS2 gene inactivation. Hum Mutat (2007) 0.99

Methylome analysis reveals Jak-STAT pathway deregulation in putative breast cancer stem cells. Epigenetics (2011) 0.97

TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma. PLoS One (2012) 0.96

New insights into BS69 functions. J Biol Chem (2006) 0.95

BTG2, its family and its tutor. Bull Cancer (2004) 0.94

Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma. J Clin Oncol (2005) 0.93

The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene (2002) 0.93

Genome-wide analysis of gene expression in neuroblastomas detected by mass screening. Cancer Lett (2004) 0.92

BTG2(TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells. Oncogene (2002) 0.91

Mutational targets in colorectal cancer cells with microsatellite instability. Fam Cancer (2006) 0.91

Enveloped particles in the serum of chronic hepatitis C patients. Virology (2005) 0.91

Protein chip array profiling analysis of sera from neuroblastoma patients. Cancer Lett (2005) 0.90

Chfr inactivation is not associated to chromosomal instability in colon cancers. Oncogene (2003) 0.89

Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: reactions and behavior after the disclosure of a positive test result. Cancer Epidemiol Biomarkers Prev (2002) 0.88

TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J Bone Miner Res (2014) 0.88

Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells. J Immunother (2010) 0.88

Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer (2008) 0.87

PLA2R1 kills cancer cells by inducing mitochondrial stress. Free Radic Biol Med (2013) 0.87

Failsafe program escape and EMT: a deleterious partnership. Semin Cancer Biol (2011) 0.87

Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood (2010) 0.87

CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. Blood (2011) 0.86

Variants in the netrin-1 receptor UNC5C prevent apoptosis and increase risk of familial colorectal cancer. Gastroenterology (2011) 0.86

Copper isotope effect in serum of cancer patients. A pilot study. Metallomics (2015) 0.84

Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer (2006) 0.84

Tif1γ is essential for the terminal differentiation of mammary alveolar epithelial cells and for lactation through SMAD4 inhibition. Development (2012) 0.84

Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer (2002) 0.84

Intensity-dependent constitutional MLH1 promoter methylation leads to early onset of colorectal cancer by affecting both alleles. Genes Chromosomes Cancer (2010) 0.84

The SNAIL family member SCRATCH1 is not expressed in human tumors. Oncol Rep (2010) 0.83

Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribine. Biochem Pharmacol (2003) 0.82

Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphisms. Hum Mutat (2002) 0.82

Plasticity of melanoma and EMT-TF reprogramming. Oncotarget (2014) 0.82

Early origin of cancer metastases: dissemination and evolution of premalignant cells. Cell Cycle (2008) 0.82

UVB-induced G2 arrest of human melanocytes involves Cdc2 sequestration by Gadd45a in nuclear speckles. Cell Cycle (2006) 0.82

Interhelical loops within the bHLH domain are determinant in maintaining TWIST1-DNA complexes. J Biomol Struct Dyn (2013) 0.80

ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells. Mol Cancer (2014) 0.80

The LIM domain protein Lmo2 binds to AF6, a translocation partner of the MLL oncogene. FEBS Lett (2002) 0.79

βIII-Tubulin is required for interphase microtubule dynamics in untransformed human mammary epithelial cells. Eur J Cell Biol (2011) 0.78

Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. Pediatr Blood Cancer (2011) 0.78

Weekly administration of paclitaxel induces long-term aneugenicity in nude mice. Cancer Biol Ther (2007) 0.78

Retraction notice to "Structure and functional analysis of the MYND domain" [J. Mol. Biol. (2006) 358, 498-508]. J Mol Biol (2008) 0.77

Modulation of oxidative stress by twist oncoproteins. PLoS One (2013) 0.76

p21(Cip1) regulates cell-substrate adhesion and interphase microtubule dynamics in untransformed human mammary epithelial cells. Eur J Cell Biol (2011) 0.76

[Tumour genomics: an unstable landscape]. Bull Cancer (2008) 0.75

Should we consider cancers as embryonic diseases or as consequences of stem-cell deregulation? Clin Med Oncol (2008) 0.75

Upstream ORF affects MYCN translation depending on exon 1b alternative splicing. BMC Cancer (2009) 0.75

[microRNA in cancer, small but risky]. Med Sci (Paris) (2008) 0.75

[The key implication of early migration of metastatic cells]. Med Sci (Paris) (2009) 0.75

[Immunotherapy of poor-prognosis neuroblastoma in children: from bench to bedside]. Bull Cancer (2006) 0.75

[The premature senescence: chimera, saving angel or Dr Jekyll and Mr Hyde?]. Med Sci (Paris) (2009) 0.75

[An alternate model of tumoral progression]. Biol Aujourdhui (2011) 0.75